文献速递胸部肿瘤放疗放疗物理与技术

早期非小细胞肺癌立体定向消融放疗后野内复发分析与报告改进方法

An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2020-02-13

该研究提出一种标准化方法,将复发时诊断CT与初始治疗计划图像经形变配准融合,结合剂量学参数与复发肿瘤几何信息,对SABR后野内复发进行分类。2004至2014年634例接受SABR的患者中48例局部复发,35例图像可评估,其中16例为野内复发:9例中央高剂量、6例周边高剂量、1例两者兼有。中央高剂量复发多于周边高剂量,提示多数野内失败可能源于生物学而非技术因素。

要点

  • 复发CT与初始计划CT形变配准,可量化rGTV实际受照剂量。
  • 野内复发按rGTVD95%是否≥PTV处方剂量的95%分为中央/周边高剂量。
  • 中央高剂量复发多于周边高剂量,提示生物学因素为主。

核心结论

  • 报告了一种SABR后野内复发分析与分类的标准化方法,中央高剂量复发多于周边高剂量,提示多数野内失败可能为生物学而非技术原因。

研究设计与样本

  • 回顾性方法学研究,纳入2004至2014年接受SABR的634例早期NSCLC患者,其中48例局部复发,35例有可评估图像。

主要发现

  • 35例可评估图像中16例为野内复发:9例中央高剂量、6例周边高剂量、1例两者兼有。
  • 中央与周边高剂量复发的复发时间和复发体积无统计学差异。
  • 中央高剂量复发的平均rGTV剂量、平均质心剂量和rGTVD95%均高于周边高剂量复发。

关键数值与推荐

  • 野内失败定义为复发肿瘤质心位于原计划靶区(PTV)内。
  • 中央高剂量复发定义为rGTVD95%≥PTV处方剂量的95%,周边高剂量复发定义为rGTVD95%<PTV处方剂量的95%。

临床怎么用

  • 可将复发时诊断CT与初始计划图像形变配准,计算rGTV剂量分布,按质心位置和rGTVD95%对野内复发进行标准化分类。

局限性

  • 原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patterns of local, regional, and distant failure after stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC) have been widely reported. However, reliable methods for analyzing causes of local failure are lacking. We describe a method for analyzing and reporting patterns of in-field recurrence after SABR, incorporating dosimetric parameters from initial treatment plan as well as geometric information from diagnostic images at recurrence. MATERIAL AND METHODS: Diagnostic CT images at recurrence were registered with initial treatment planning images and radiation dose by deformable image registration. Recurrent gross tumor volume (rGTV) and centroid (geometric center of rGTV) were delineated. In-field failure was classified as centroids originating within the original planning target volume. Dose-volume histograms for each rGTV were used to further classify in-field recurrences as central high-dose (dose to 95% of rGTV [rGTVD95%] ≥95% of dose prescribed to PTV) or peripheral high-dose (rGTVD95% <95% of dose prescribed to PTV). RESULTS: 634 patients received SABR from 2004 to 2014 with 48 local recurrences. 35 of these had evaluable images with 16 in-field recurrences: 9 central high-dose, 6 peripheral high-dose, and 1 had both. Time to and volume of recurrence were not statistically different between central versus peripheral high-dose recurrences. However mean rGTV dose, mean centroid dose, and rGTVD95% were higher for central versus peripheral high-dose recurrences. CONCLUSION: We report a standardized method for analysis and classification of in-field recurrence after SABR. There were more central as opposed to peripheral high-dose recurrences, suggesting biological rather than technical issues underlying majority of in-field failures.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Nantavithya C, Gomez DR, Chang JY, et al. An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer. Radiother Oncol. 2020. PMID: 32062325. doi:10.1016/j.radonc.2020.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。